Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, has reported its financial results for the year ended December 31, 2025, alongside a corporate update. The company highlighted significant progress in its clinical trials, particularly the REVEAL pivotal trial for TSHA-102, which targets Rett syndrome. Multiple patients have been dosed, and the company is on track to complete dosing in the second quarter of 2026. Additionally, Taysha received FDA clearance to initiate the ASPIRE trial, which will include safety data for patients aged 2 to <4 years in its planned Biologics License Application (BLA) submission. The company maintained a favorable tolerability profile with no treatment-related serious adverse events reported in the ongoing trials. Financially, Taysha reported a net loss of $109 million for 2025, an increase from the previous year's loss of $89 million, primarily due to increased research and development expenses. The company ended the year with $319.8 million in cash and cash equivalents, sufficient to fund operations into 2028. Taysha's management expressed optimism about the upcoming milestones and the potential for TSHA-102 to address the genetic root cause of Rett syndrome, a condition with significant unmet medical needs.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.